Search

Displaying results 8601 - 8610 of 9667 in total
  1. Drug

    Friluglanstat

    go.drugbank.com/drugs/DB21652
    Experimental

    Friluglanstat has a monoisotopic molecular weight of 516.12 Da.

  2. Drug

    Canlitinib

    go.drugbank.com/drugs/DB21656
    Experimental

    Canlitinib has a monoisotopic molecular weight of 619.21 Da.

  3. Drug

    Labuxtinib

    go.drugbank.com/drugs/DB21658
    Experimental

    Labuxtinib has a monoisotopic molecular weight of 377.13 Da.

  4. Drug

    CGC-11047

    go.drugbank.com/drugs/DB05722
    Investigational

    CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

  5. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. … Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  6. Drug

    5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine

    go.drugbank.com/drugs/DB08666
    Experimental

    These are aromatic compounds containing at least one benzene ring. This drug targets the protein methionine aminopeptidase.

  7. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696]

  8. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

  9. Drug

    DYNE-251

    go.drugbank.com/drugs/DB18130
    Investigational

    It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.

  10. Drug

    BO-653

    go.drugbank.com/drugs/DB19216
    Investigational

    BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and